Protective effects of the angiotensin type 1 receptor antagonist losartan in infection-induced and arthritis-associated alveolar bone loss

Journal of Periodontal Research

Volumn 50, Issue 6, 2015, Pages 814-823

  Queiroz Junior, C M ^a   Silveira, K D ^a   de Oliveira, C R ^a   Moura, A P ^a   Madeira, M F M ^a   Soriani, F M ^a   Ferreira, A J ^a   Fukada, S Y ^b   Teixeira, M M ^a   Souza, D G ^a   da Silva, T A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alveolar bone; Angiotensin; Arthritis; Losartan; Periodontal disease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIINFLAMMATORY AGENT; LOSARTAN;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ALVEOLAR BONE LOSS; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; COMPLICATION; CYTOCHEMISTRY; DRUG EFFECTS; KNEE; MALE; MAXILLA; METABOLISM; MICROBIOLOGY; MOUSE; PASTEURELLACEAE INFECTION; PATHOGENICITY; PATHOLOGY; RAW 264.7 CELL LINE; SERUM;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ALVEOLAR BONE LOSS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; HISTOCYTOCHEMISTRY; KNEE JOINT; LOSARTAN; MALE; MAXILLA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PASTEURELLACEAE INFECTIONS; RAW 264.7 CELLS; RECEPTOR, ANGIOTENSIN, TYPE 1; SERUM;

EID: 84945471040     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12269     Document Type: Article

References (37)

1. Goldring SR, Purdue PE, Crotti TN et al. Bone remodelling in inflammatory arthritis. Ann Rheum Dis 2013;72:ii52-ii55.
2. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012;11:234-250.
3. Garlet GP. Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res 2010;89:1349-1363.
4. Graves DT, Li J, Cochran DL. Inflammation and uncoupling as mechanisms of periodontal bone loss. J Dent Res 2011;90:143-153.
5. Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol 2011;38:60-84.
6. Lamparter S, Kling L, Schrader M, Ziegler R, Pfeilschifter J. Effects of angiotensin II on bone cells in vitro. J Cell Physiol 1998;175:89-98.
7. Price A, Lockhart JC, Ferrell WR, Gsell W, McLean S, Sturrock RD. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis. Arthritis Rheum 2007;56:441-447.
8. Shimizu H, Nakagami H, Osako MK et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008;22:2465-2475.
9. Santos CF, Akashi AE, Dionísio TJ et al. Characterization of a local renin-angiotensin system in rat gingival tissue. J Periodontol 2009;80:130-139.
10. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-329.
11. Asaba Y, Ito M, Fumoto T et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 2009;24:241-250.
12. Silveira KD, Coelho FM, Vieira AT et al. Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Peptides 2013;46:53-63.
13. Araújo AA, Souza TO, Moura LM et al. Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model. J Clin Periodontol 2013;40:1104-1111.
14. Araújo AA, Lopes de Souza G, Souza TO et al. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn Schmiedebergs Arch Pharmacol 2013;386:875-884.
15. Suda N, Moriyama K, Ganburged G. Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome. Infect Immun 2013;81:182-188.
16. Madeira MFM, Queiroz-Junior CM, Costa GM et al. MIF induces osteoclast differentiation and contributes to progression of periodontal disease in mice. Microbes Infect 2012;14:198-206.
17. Madeira MFM, Queiroz-Junior CM, Costa GM et al. Platelet-activating factor receptor blockade ameliorates Aggregatibacter actinomycetemcomitans-induced periodontal disease in mice. Infect Immun 2013;81:4244-4251.
18. Queiroz-Junior CM, Madeira MFM, Coelho FM et al. Experimental arthritis triggers periodontal disease in mice: involvement of TNF-α and the oral microbiota. J Immunol 2011;187:3821-3830.
19. Queiroz-Junior CM, Bessoni RL, Costa VV, Souza DG, Teixeira MM, Silva TA. Preventive and therapeutic anti-TNF-α therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice. Life Sci 2013;93:423-428.
20. -ΔΔCt method. Methods 2001;25:402-408.
21. Izu Y, Mizoguchi F, Kawamata A et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 2009;8:4857-4864.
22. Queiroz-Junior CM, Madeira MM, Coelho FM et al. Experimental arthritis exacerbates Aggregatibacter actinomycetemcomitans-induced periodontitis in mice. J Clin Periodontol 2012;39:608-616.
23. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1997;152:5-10.
24. Kawakami Y, Matsuo K, Murata M et al. Expression of angiotensin II receptor-1 in human articular chondrocytes. Arthritis 2012;2012:648537.
25. Mateo T, Abu Nabah YN, Abu Taha M et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006;176:5577-5586.
26. Nabah YN, Mateo T, Estelles R et al. AngiotensinII induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004;110:3581-3586.
27. Kantarci A, Oyaizu K, Van Dyke TE. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003;74:66-75.
28. Corrêa JD, Madeira MF, Resende RG et al. Association between polymorphisms in interleukin-17A and -17F genes and chronic periodontal disease. Mediators Inflamm 2012;2012:846052.
29. Garlet GP, Cardoso CR, Campanelli AP et al. The essential role of IFN-gamma in the control of lethal Aggregatibacter actinomycetemcomitans infection in mice. Microbes Infect 2008;10:489-496.
30. Queiroz-Junior CM, Silva MJ, Corrêa JD et al. A controversial role for IL-12 in immune response and bone resorption at apical periodontal sites. Clin Dev Immunol 2010;2010:327417.
31. Takayanagi H, Ogasawara K, Hida S et al. T-cell mediated regulation of osteoclastogenesis by signalling crosstalk between RANKL and IFN-γ. Nature 2000;408:600-605.
32. Yu JJ, Ruddy MJ, Wong GC et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 2007;109:3794-3802.
33. Suda K, Woo JT, Takami M, Sexton PM, Nagai K. Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-a, IL-1, and RANKL. J Cell Physiol 2002;190:101-108.
34. Fives-Taylor PM, Meyer DH, Mintz KP, Brissette C. Virulence factors of Actinobacillus actinomycetemcomitans. Periodontol 2000 1999;20:136-167.
35. Yoshimura A, Hara Y, Kaneko T, Kato I. Secretion of IL-1β, TNF-α, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontapathic bacteria. J Periodont Res 1997;32:279-286.
36. Gao Y, Grassi F, Ryan MR et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007;117:122-132.
37. Yago T, Nanke Y, Kawamoto M et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007;9:R96.